Business UpdateJun 15, 2026, 07:03 AM
Pasithea to Engage NF1 Community at CTF Conference for PAS-004
AI Summary
Pasithea Therapeutics Corp. announced its participation as an exhibitor at the Children's Tumor Foundation (CTF) 2026 NF Conference in Denver, Colorado, from June 26-30, 2026. The company aims to engage directly with the NF1 community regarding its lead treatment candidate, PAS-004, a next-generation macrocyclic MEK inhibitor. This follows recent FDA Fast Track and Rare Pediatric Disease Designations for PAS-004, which is currently in Phase 1 clinical trials for advanced cancer and NF1-associated plexiform neurofibromas.
Key Highlights
- Pasithea Therapeutics to exhibit at the Children's Tumor Foundation (CTF) 2026 NF Conference in Denver.
- Conference scheduled for June 26-30, 2026.
- Company to engage with the NF1 community regarding lead treatment candidate PAS-004.
- PAS-004 recently received FDA Fast Track Designation.
- PAS-004 also received Rare Pediatric Disease Designation.
- CEO Dr. Tiago Reis Marques emphasized commitment to developing better-tolerated NF1 therapies.
- PAS-004 is a next-generation macrocyclic MEK inhibitor.
- PAS-004 is in Phase 1 trials for advanced cancer and NF1-associated plexiform neurofibromas.
Price Impact
More from KTTA